（编辑 姚尧） 证券日报网讯 1月28日，康恩贝在互动平台回答投资者提问时表示，企业"反内卷"的本质在于持续构建 难以替代的核心竞争力。为此，公司系统规划并着力打造四大核心能力：健康领域全链条品牌塑造能 力、前瞻性研发与管线布局能力、全渠道专业合规推广能力、稳定高效供应链能力，以此筑牢发展根基 与竞争壁垒，驱动经济效益与企业价值同步提升。在拓宽营收渠道方面，公司坚持内涵式增长与外延式 扩张双轮驱动。在内涵式增长方面，公司将巩固优势品种品牌如肠炎宁、前列康、至心砃等的领导地 位；挖掘潜力品种如金笛、牛黄上清胶囊、金艾康等系列产品增长机会；洞察市场机会并完善研发布 局，巩固中药大健康的优势并积极布局创新药，寻找新的增长点。在外延式扩张方面，一方面围绕中药 大健康的股权并购，另一方面公司将通过系统化BD快速获取潜力品种，丰富管线。 ...

Core Viewpoint - The company, Kang En Bei, has appointed Ying Xu as the new chairman of its board of directors, effective immediately, marking a significant leadership change within the organization [1][5]. Company Overview - Kang En Bei, founded in 1969, has evolved from a local pharmaceutical factory into one of the largest traditional Chinese medicine companies in Zhejiang Province and ranks among the top in China's traditional medicine industry [3][7]. - The company was listed on the Shanghai Stock Exchange in 2004 and initiated a major brand development project in 2017, which included well-known trademarks such as Kang En Bei, Qian Lie Kang, Zhen Shi Ming, and Tian Bao Ning [3][7]. Leadership Change - Ying Xu, born in 1973 and a graduate of Shenyang Pharmaceutical University, has held various leadership roles in the pharmaceutical industry, including positions at Zhejiang Yingte Pharmaceutical Co., Ltd. and Zhejiang Yingte Group Co., Ltd. [3][7]. - As of the announcement, Ying Xu does not hold any shares in Kang En Bei [3][7]. Business Transformation - Following a mixed-ownership reform in 2020, Kang En Bei transitioned from a private enterprise to a state-controlled company, with the Zhejiang Provincial State-owned Assets Supervision and Administration Commission as its actual controller [4][8]. - The company operates in multiple sectors, including traditional Chinese medicine, chemical medicine, and health consumer products, boasting over ten billion-yuan brands such as Chang Yan Ning and Qian Lie Kang [4][8]. Financial Performance - In the first three quarters of 2025, Kang En Bei reported a revenue of 4.976 billion yuan, reflecting a year-on-year growth of 1.27%, while the net profit attributable to shareholders reached 584 million yuan, up by 12.65% [5][8]. - The Chang Yan Ning series is projected to achieve sales exceeding 1.5 billion yuan in 2024, maintaining its position as the market leader in the domestic retail market for intestinal medications [4][8].